Key result
EGFR/IGF1R inhibition improves relaxation in HCM cardiomyocytes, revealed by screening 157 kinase inhibitors.
Why the study?
Therapies improving cardiac relaxation in conditions like HCM are scarce, partly due to a limited understanding of modulators of cardiomyocyte relaxation and kinase dysregulation.
Do EGFR/IGF1R signaling inhibitors improve cardiomyocyte relaxation in hypertrophic cardiomyopathy models?
Do EGFR/IGF1R signaling inhibitors improve cardiomyocyte relaxation in hypertrophic cardiomyopathy models?
Inhibition of EGFR/IGF1R signaling improves cardiomyocyte relaxation, presenting a novel potential therapeutic target for diastolic dysfunction in hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for EGFR/IGF1R inhibition in HCM diastolic dysfunction; should not change practice pending human validation.
BACKGROUND: Diastolic dysfunction is central to diseases such as heart failure with preserved ejection fraction and hypertrophic cardiomyopathy (HCM). However, therapies that improve cardiac relaxation are scarce, partly due to a limited understanding of modulators of cardiomyocyte relaxation. We hypothesized that cardiac relaxation is regulated by multiple unidentified proteins and that dysregulation of kinases contributes to impaired relaxation in patients with HCM. METHODS: We optimized and increased the throughput of unloaded shortening measurements and screened a kinase inhibitor library in isolated adult cardiomyocytes from wild-type mice. One hundred fifty-seven kinase inhibitors were screened. To assess which kinases are dysregulated in patients with HCM and could contribute to impaired relaxation, we performed a tyrosine and global phosphoproteomics screen and integrative inferred kinase activity analysis using HCM patient myocardium. Identified hits from these 2 data sets were validated in cardiomyocytes from a homozygous MYBPC3 c.2373insG HCM mouse model. RESULTS: Screening of 157 kinase inhibitors in wild-type (N=33) cardiomyocytes (n=24 563) resulted in the identification of 17 positive inotropes and 21 positive lusitropes, almost all of them novel. The positive lusitropes formed 3 clusters: cell cycle, EGFR (epidermal growth factor receptor)/IGF1R (insulin-like growth factor 1 receptor), and a small Akt (α-serine/threonine protein kinase) signaling cluster. By performing phosphoproteomic profiling of HCM patient myocardium (N=24 HCM and N=8 donors), we demonstrated increased activation of 6 of 8 proteins from the EGFR/IGFR1 cluster in HCM. We validated compounds from this cluster in mouse HCM (N=12) cardiomyocytes (n=2023). Three compounds from this cluster were able to improve relaxation in HCM cardiomyocytes. CONCLUSIONS: We showed the feasibility of screening for functional modulators of cardiomyocyte relaxation and contraction, parameters that we observed to be modulated by kinases involved in EGFR/IGF1R, Akt, cell cycle signaling, and FoxO (forkhead box class O) signaling, respectively. Integrating the screening data with phosphoproteomics analysis in HCM patient tissue indicated that inhibition of EGFR/IGF1R signaling is a promising target for treating impaired relaxation in HCM.
No takes yet. Share an insight, caveat, or question.
Algül et al. (2023) studied Hypertrophic cardiomyopathy (n=32). Kinase inhibitors (EGFR/IGF1R signaling inhibitors) was evaluated on Identification of positive inotropes and lusitropes, and phosphoproteomic profiling. Screening of 157 kinase inhibitors identified 21 positive lusitropes, revealing that inhibition of EGFR/IGF1R signaling improves relaxation in hypertrophic cardiomyopathy cardiomyocytes.
Synapse has enriched 10 related papers. Consider them for comparative context: